drugset / Trial / NCT00471432

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

NCT00471432

Phase 1 Completed 40 enrolled NCIC Clinical Trials Group
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving OGX-011 together with docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of OGX-011 when given together with docetaxel in treating patients with metastatic or locally recurrent solid tumors.

Timeline

Start
2003-04-04
Primary completion
2006-03-09
Completion
2009-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 30 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject custirsen Antisense oligonucleotide 40 mg Intravenous
Subject custirsen Antisense oligonucleotide 640 mg Intravenous